Troponins in Heart Failure - a Perpetual Challenge
1Cardiology Department, Bucharest Emergency University Hospital, Bucharest, Romania.
Insights
Elevated troponin levels in heart failure (HF) indicate underlying issues and predict outcomes. High-sensitivity troponin testing aids diagnosis but requires careful interpretation for acute myocardial infarction versus other cardiac injuries.
Area of Science:
- Cardiology
- Biomarker Research
- Clinical Diagnostics
Background:
- Increased cardiac troponin (cTn) levels are common in heart failure (HF), correlating with pathogenesis, diagnosis, and prognosis.
- High-sensitivity troponin assays (hs-cTn) improve detection but complicate interpretation compared to conventional troponin testing.
- Elevated cTn in HF can signify acute myocardial infarction (AMI) if other diagnostic criteria are met.
Discussion:
- Sub-AMI threshold elevations in cTn suggest acute or chronic myocardial injury, identifiable through serial testing trends.
- In both acute and chronic HF, elevated cTn levels are significant prognostic indicators for adverse cardiovascular events.
- Differential diagnosis is crucial, as various conditions like hypertensive crises, arrhythmias, myocarditis, and stroke can transiently increase cTn levels, mimicking acute coronary syndrome (ACS).
Key Insights:
- Multiple mechanisms contribute to elevated cTn, including myocardial necrosis, coronary thrombosis, ischemia-reperfusion injury, inflammation, and neurohormonal activation.
- hs-cTn screening in high-risk populations provides prognostic information regarding new-onset HF and other cardiovascular events.
- Understanding cTn kinetics and clinical context is vital for accurate diagnosis and risk stratification in HF patients.
Outlook:
- Further research into the precise mechanisms of cTn elevation in non-AMI HF is warranted.
- Standardized interpretation guidelines for hs-cTn in HF are needed to improve clinical decision-making.
- Integrating cTn data with other clinical and imaging findings will enhance personalized risk assessment and management strategies.
Abstract:
Increased troponin levels in HF are a frequent and significant finding, as it strongly correlates with the underlying pathogenic mechanisms, diagnosis and prognosis. The advent of hs-cTn testing, as opposed to conventional troponin testing, led to additional difficulties in result interpretation. Most frequently, though not exclusively, increased cTn levels in acute or chronic failure is correlated, with myocardial necrosis (AMI); the diagnosis of AMI is confirmed if other criteria are fulfilled, as described in the fourth Universal Definition of Myocardial Infarction. Increased cTn levels below the cut-off for AMI suggest acute or chronic injury, depending on the ascending and/or descending trend curve or stable levels of cTn on serial testing. In acute or chronic HF with reduced or preserved EF, increased cTn levels carry prognostic value for adverse outcomes. Acute and chronic HF, as well as other ischemic or non-ischemic conditions, may lead to a transient increase in cTn levels: hypertensive crises, tachyarrhythmias, valvular regurgitation, myocarditis, stroke, mandating differential diagnosis with ACS. There are multiple mechanisms that explain increased levels of cTn: myocardial necrosis or coronary thrombosis (type I MI), supply-demand mismatch with subendocardial ischemia/injury, cardiomyocyte apoptosis, inflammatory cytokines, neurohomonal changes. Screening for cTn levels in the population at high cardiovascular risk yields prognostic information on development of de novo HF or other cardiovascular adverse events.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:26Heart Failure Drugs: Inotropic Agents
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:29Heart Failure II: Pathophysiology
01:30Acute Coronary Syndrome I: Introduction
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System